Chemomab Therapeutics (NASDAQ:CMMB) Shares Up 0.5% – Should You Buy?

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) shares were up 0.5% during mid-day trading on Wednesday . The stock traded as high as $2.19 and last traded at $2.08. Approximately 217,347 shares changed hands during mid-day trading, an increase of 108% from the average daily volume of 104,315 shares. The stock had previously closed at $2.07.

Wall Street Analyst Weigh In

Separately, Oppenheimer reissued an “outperform” rating and issued a $11.00 price objective (down previously from $13.00) on shares of Chemomab Therapeutics in a research note on Friday, November 15th.

Chemomab Therapeutics Stock Performance

The firm’s 50-day simple moving average is $1.92 and its two-hundred day simple moving average is $1.65. The stock has a market cap of $29.87 million, a price-to-earnings ratio of -2.08 and a beta of 0.66.

Institutional Investors Weigh In On Chemomab Therapeutics

A hedge fund recently bought a new stake in Chemomab Therapeutics stock. Sphera Funds Management LTD. acquired a new position in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,214,575 shares of the company’s stock, valued at approximately $1,907,000. Sphera Funds Management LTD. owned 8.46% of Chemomab Therapeutics as of its most recent SEC filing. Institutional investors own 46.05% of the company’s stock.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).